Natali Simone, Screpis Daniele, Patania Edoardo, De Berardinis Luca, Benoni Andrea, Piovan Gianluca, Iacono Venanzio, Magnan Bruno, Gigante Antonio Pompilio, Zorzi Claudio
Department of Orthopaedics, IRCCS Ospedale Sacro Cuore Don Calabria, 37024 Negrar, Italy.
Department of Orthopaedics and Trauma Surgery, University of Verona, Piazzale A. Stefani 1, 37136 Verona, Italy.
J Pers Med. 2023 Aug 26;13(9):1309. doi: 10.3390/jpm13091309.
Glenohumeral osteoarthritis (GOA) is associated with disabling shoulder pain that affects everyday life. Its management comprises various treatment approaches, both conservative and surgical. Regenerative medicine has gained a major role in the conservative treatment of osteoarthritis. Intra-articular injection of adipose-derived mesenchymal stem cells (ADMSCs) is a widely used regenerative medicine approach. The aim of this retrospective study was to report the safety and clinical outcomes of intra-articular injection of ADMSCs in patients with GOA over 36-months.
This retrospective observational study involved patients with chronic shoulder pain resistant to standard conservative treatment and a diagnosis of concentric GOA, who received an intra-articular injection of autologous micro-fragmented adipose tissue (μFAT). The values of the Constant-Murley score (CMS), the visual analog scale (VAS), and the simple shoulder test (SST), collected at baseline and at 12, 24, and 36 months, were analyzed to assess treatment efficacy. The single assessment numeric evaluation (SANE) was used to rate patient satisfaction. The Friedman test was used to compare observations of CMS, VAS, and SST values repeated on the same subjects. The significance threshold was set at 0.05.
The participants were 65 patients with a mean age of 54.19 years and a nearly equal gender distribution. Most had mild concentric GOA classified as Samilson-Prieto grade 1. The mean follow-up duration was 44.25 months. The postoperative clinical scores showed significant improvement. At 36 months, the CMS was 84.60, the VAS score was 3.34, and the SST score was 10.15 (all < 0.0001). The SANE score at 36 months indicated that 54 patients (83.08%) were completely satisfied with the treatment.
ADMSC treatment exerted favorable effects on the clinical outcomes of patients with GOA, providing pain relief and improving shoulder function. Our data support its use as a conservative treatment option for osteoarthritis.
肩肱关节骨关节炎（GOA）与影响日常生活的致残性肩部疼痛相关。其治疗包括多种保守和手术治疗方法。再生医学在骨关节炎的保守治疗中发挥了重要作用。关节内注射脂肪间充质干细胞（ADMSCs）是一种广泛应用的再生医学方法。这项回顾性研究的目的是报告关节内注射ADMSCs治疗GOA患者超过36个月的安全性和临床结果。
这项回顾性观察性研究纳入了对标准保守治疗无效且诊断为同心性GOA的慢性肩部疼痛患者，他们接受了关节内注射自体微片段脂肪组织（μFAT）。分析在基线以及12、24和36个月时收集的Constant-Murley评分（CMS）、视觉模拟量表（VAS）和简单肩部测试（SST）值，以评估治疗效果。使用单评估数值评估（SANE）来评定患者满意度。采用Friedman检验比较同一受试者重复测量的CMS、VAS和SST值。显著性阈值设定为0.05。
参与者为65例患者，平均年龄54.19岁，性别分布几乎相等。大多数患者患有轻度同心性GOA，分类为Samilson-Prieto 1级。平均随访时间为44.25个月。术后临床评分显示有显著改善。在36个月时，CMS为84.60，VAS评分为3.34，SST评分为10.15（均P<0.0001）。36个月时的SANE评分表明，54例患者（83.08%）对治疗完全满意。
ADMSC治疗对GOA患者的临床结果产生了有利影响，缓解了疼痛并改善了肩部功能。我们的数据支持将其用作骨关节炎的保守治疗选择。
